MEI Pharma names new director
4 July 2019 -

MEI Pharma Inc (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, announced yesterday that it has named Tamar Howson as its new director.

Howson is an experienced business development executive and consultant with more than 30 years of service in the pharmaceutical and biotechnology industries. She presently serves on the board of directors of Organovo Holdings Inc and Scientus Pharma. Between 2009 to 2018 she served on the boards of various other life sciences companies including Actavis plc, Aradigm Corporation, ContraVir Pharmaceuticals Inc, Cynapsus Therapeutics Inc, Enzymotec PLC, Idenix Pharmaceuticals Inc and OXiGENE Inc.

From 2009 to 2011, she served as a member of the transaction advisory firm JSB-Partners, providing business development support to life sciences companies. From 2007 to 2008, she served as executive vice president, Corporate Business Development at Lexicon Pharmaceuticals. Prior to joining Lexicon, she served as senior vice president, Corporate and Business Development at Bristol-Myers Squibb and SmithKline Beecham plc.

Christine A White, MD, chairman of the board, MEI Pharma, said, 'We are very happy to have Tamar join the MEI board; her vast industry, transaction and leadership experience will be highly valuable to the company as we continue to advance our pipeline and the company's strategy and business matures.'